PayPal and eBay reach a fork in the road, announce 2015 split following pressure from Icahn EU targets Apple's overseas tax model, says Ireland appears to grant firm illegal rebate News Corp. to buy online real estate business Move for $950 million in cash Global stocks mostly higher as traders monitor Hong Kong protests, economic data Walgreen matches 4 Q profit expectations, tops revenue forecasts Ukrainians rush to prepare for a cold winter without Russian gas if talks fail China approves iPhone 6 after Apple promises no' backdoors'; Apple says sales start Oct. 17 Ford shares fall as company says it no longer expects Europe profit in 2015 With eurozone inflation at near five-year low, European Central Bank under pressure to do more Drugmaker Pfizer, aiming to raise sales of its Viagra, starts new ad campaign targeting women» Read More
It just keeps getting worse. Pfizer, which is staring down the loss of a $13 billion-a-year drug (Lipitor) in the 2010-11 timeframe, needs the rest of its product portfolio and its drug development pipeline to be firing on all cylinders.
Which stocks will be the winners and losers under an Obama administration? And how about McCain?
So, Carl Icahn is grabbing headlines this week over his new battle with Yahoo and how Boone Pickens is backing him up now, too. But Icahn has his finger in a lot of pies. He's still in a proxy fight with Biogen Idec where he's trying to get his people on the Board at the upcoming shareholder meeting on June 19th.
Sanofi-Aventis' experimental drug aflibercept failed to meet its goal in a mid-stage ovarian cancer study but the French drug maker said on Wednesday it had shown some promising signs of effectiveness.
If sales of Amgen's anemia drugs hadn't fallen so much last year, the American biotechnology industry probably would have turned its first profit in history. That's one of the main conclusions of Ernst & Young's comprehensive annual report on the sector that came out today.
A study claims "the time has come" for researchers to study ED drugs as preventive medicine for the heart.
Up until last month, AMGN had been atop the list of pharmaceutical manufacturer donors and PFE was in a close second. But the CRP says they flip-flopped in the most recent month that figures are available. So far, in the 2008 election cycle, Pfizer's given $862,000 to candidates and Amgen has forked over $852,000.
There's way too much stuff out of ASCO to do a comprehensive blog entry that would satisfy readers--especially small-cap biotechies. I mean, there are literally thousands of pages of research being published today by analysts on the new data.
Genentech said on Thursday a trial of Avastin in colon cancer patients who have undergone surgery will be completed earlier than expected due to faster collection of data and a higher-than-planned number of patients with stage III cancer.
Traders will be glued to the web Thursday night as thousands of cancer studies go online. What’s the trade as these studies potentially send shock waves through biotech stocks on Friday morning?
This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.
I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
I realize it's become a bit of a tired tagline, but through the magic of live webcasts what happens in Vegas doesn't stay in Vegas. This morning Dendreon was first at bat at the Bank of America Healthcare Conference in Sin City.
So, I admit I watched a lot of television last night and saw a commercial for a relatively new osteoporosis-breast cancer prevention combo drug from Eli Lilly called Evista. Actually, I saw it three times.
Occasionally -- when the bosses will let me -- I take a day to network, learn and maybe pick up a story idea by attending a biotech or healthcare investment conference. Many firms put on the events for their clients and they often invite reporters to hang out. ... The PR guy told me a couple of sessions during the day would be "closed" to me. It wasn't clear what the closed sessions were all about, and so my curiousity was piqued...
Amgen is in major belt-tightening mode. Still it held its annual shareholder shindig at the swanky Four Seasons Hotel in Westlake Village, CA. The 400-500 investors who showed up were treated to valet parking, soft drinks, and a nice spread of cheeses, vegetable crudite, fruit and sweets
The market can swing as much on sentiment as fact. Investors would be wise to remember this.
Haim Israel of Merrill Lynch in Jerusalem has some ideas about smaller Israeli companies that might have escaped the attention of U.S. investors.
There's no money left under the pillow, but Amgen execs and directors have been handed a gift. One of the most outspoken, large, individual investors in the biotech company who's been calling for the Board and CEO to go won't be attending its annual shareholder meeting after all.
Too few influential doctors are telling the public if they have financial ties to the companies that make lifesaving drug-coated stents.